Axsome Therapeutics, Inc. (AXSM): auditor change — Axsome Therapeutics dismisses Ernst & Young, appoints Deloitte as auditor

Axsome Therapeutics, Inc.

Audit Committee approved dismissal of Ernst & Young and engagement of Deloitte & Touche for FY2023, effective June 30, 2023.
Ernst & Young's reports on FY2021 and FY2022 financials were unqualified; no disagreements or reportable events.
No consulting with Deloitte prior to engagement on accounting principles or audit matters.
Ernst & Young furnished a letter agreeing with the disclosures, attached as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Axsome Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: Deloitte & Touche LLP

Exact text from the filing

On June 22, 2023, Ernst & Young LLP (“Ernst & Young”) was informed that the Committee approved Ernst & Young’s dismissal as the Company’s independent registered public accounting firm with such dismissal to be effective as of June 30, 2023.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Axsome Therapeutics, Inc. engaged Deloitte & Touche LLP as its auditor.

Action: engagement
Auditor: Deloitte & Touche LLP

Exact text from the filing

On June 22, 2023, the Audit Committee (the “Committee”) of the Board of Directors of Axsome Therapeutics, Inc. (“we,” “our,” “us,” or the “Company”) approved the engagement of Deloitte & Touche LLP (“Deloitte”), to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023 with such appointment to be effective as of June 30, 2023.

View on SEC.gov

Browse all auditor changes →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-029901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.